Medical Health Cluster


Evusheld Reduces COVID-19 Disease Severity Among Unvaccinated Adults

Tixagevimab plus cilgavimab, a SARS-CoV-2–neutralizing monoclonal antibody combination marketed as Evusheld, protected nonhospitalized individuals with mild to moderate COVID-19 symptoms from progressing to severe COVID-19 or death in a clinical trial. The study, published in The Lancet Respiratory Medicine, is the first to evaluate the intramuscular injection for outpatient treatment; other anti–SARS-CoV-2 […]

Read More

Age and Ferritin Levels May Predict MIS-C Severity

Older age and higher ferritin levels at hospital admission predict severe illness in COVID-related multisystem inflammatory syndrome in children (MIS-C), according to a Canadian multicenter cohort study. The adjusted absolute risk for admission to an intensive care unit (ICU) was 43.6% among children aged 6 years and older and 46.2% […]

Read More

Autoantibodies Might Affect Acute Disease Severity and Neurological Symptoms

Concentrations of autoantibodies correlate with disease severity. Why do some people get so much sicker than others with acute COVID-19? And what causes the neurological symptoms — anosmia, fatigue, encephalopathy — seen in some patients? A team from Yale employed a new technology for finding autoantibodies to 2770 extracellular and […]

Read More